Compound ID | 848

Update compound information

Efepristin

Synonym(s): RPR 106972

Class: Streptogramin

Agent Type: Semisynthetic; Small molecule; Direct acting;
Spectrum of activity: Gram-positive & Gram-negative
Mechanism of action: Protein synthesis inhibitor
Target Pathogen: Active against Haemophilus influenzae and Staphylococcus aureus
Description: Sabath L.D., Liebeler C and Kelly J. Antistaphylococcal activity of RPR 106972 (RPR 112808/RPR106950), a new oral streptogramin compared with that of twelve other antimicrobial agents. 35th-Intersci-Conf-Antimicrobial-Agents-Chemother 1995;132
Institute where first reported: Sanofi Aventis, France
Year first mentioned: 1995
Highest development stage: Phase 2
Development status: Inactive
Chemical structure(s):
Click here for structure editor
Molecular weight: 852.93
Iso. SMILES: CC[C@@H]1C(=O)N2CCC[C@H]2C(=O)N([C@H](C(=O)N3CCC(=O)C[C@H]3C(=O)N[C@H](C(=O)O[C@@H]([C@@H](C(=O)N1)NC(=O)C4=C(C=CC=N4)O)C)C5=CC=CC=C5)CC6=CC=C(C=C6)NC)C
InChI Key: PCOXSOQWQVRJCH-RIECGXCRSA-N
Can. SMILES: CC[C@@H]1C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC3=CC=C(C=C3)NC)C(=O)N4CCC(=O)C[C@H]4C(=O)N[C@@H](C5=CC=CC=C5)C(=O)O[C@H](C)[C@@H](C(=O)N1)NC(=O)C6=NC=CC=C6O
InChI: InChI=1S/C44H52N8O10/c1-5-30-41(58)51-21-10-13-31(51)42(59)50(4)33(23-26-15-17-28(45-3)18-16-26)43(60)52-22-19-29(53)24-32(52)38(55)49-36(27-11-7-6-8-12-27)44(61)62-25(2)35(39(56)47-30)48-40(57)37-34(54)14-9-20-46-37/h6-9,11-12,14-18,20,25,30-33,35-36,45,54H,5,10,13,19,21-24H2,1-4H3,(H,47,56)(H,48,57)(H,49,55)/t25-,30-,31+,32+,33+,35+,36+/m1/s1
External links:
PubChem link: https://pubchem.ncbi.nlm.nih.gov/compound/5748661
Guide to Pharmacology: efepristin
Citation: https://www.sciencedirect.com/science/article/pii/S0732889397000230?via%3Dihub

AntibioticDB is supported by GARDP.

If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.